Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2012. The report disseminates a press release from Shionogi-ViiV Healthcare LLC, a joint venture between ViiV Healthcare Ltd (a global specialist HIV company established by GSK and Pfizer) and Shionogi & Co., Ltd. The filing focuses on clinical trial results for the investigational HIV drug dolutegravir.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is a regulatory report of a clinical trial announcement rather than a financial earnings release.
Material Changes and Clinical Results
The primary material update concerns the Phase III SINGLE study (ING114467) comparing a dolutegravir-based regimen against the single tablet regimen Atripla in treatment-naïve adults with HIV-1.
- Efficacy: At 48 weeks, 88% of participants on the dolutegravir regimen achieved virological suppression (<50 copies/mL) compared to 81% on Atripla. The difference was statistically significant (p=0.003).
- Study Design: The study was designed to demonstrate non-inferiority, which was met. Statistical superiority was concluded via a pre-specified testing procedure.
- Discontinuation Rates: Discontinuation due to adverse events was 2% for the dolutegravir regimen versus 10% for Atripla.
- Adverse Events: The most common drug-related adverse events on Atripla were in the nervous system (41% of recipients), compared to 15% for the dolutegravir regimen. Gastrointestinal events were the most common for the dolutegravir regimen (22%), matching the rate for Atripla.
Outlook, Management Commentary, and Risks
Management commentary from Dr. Tsutae "Den" Nagata (Shionogi) and Dr. John Pottage (ViiV Healthcare) suggests that dolutegravir may offer an important additional first-line treatment option if approved. The SINGLE study is the second of four Phase III studies expected to report in 2012. Data from VIKING-3 and SAILING in treatment-experienced patients are anticipated later in the year to support future regulatory filings.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include the completion of clinical trials, obtaining regulatory approvals, product safety and efficacy concerns, technological advances, litigation outcomes, and changes in healthcare laws and regulations. Pfizer and GSK explicitly state they assume no obligation to update forward-looking statements.
Key Facts for Investor Verification
- Verify the regulatory status and approval timeline for dolutegravir based on the upcoming Phase III data from VIKING-3 and SAILING.
- Confirm the commercial impact of dolutegravir on the HIV portfolio of ViiV Healthcare and its contribution to GSK's future revenue.
- Monitor the safety profile of dolutegravir in treatment-experienced patients as data becomes available later in 2012.
- Review the joint venture agreement terms between GSK, Pfizer, and Shionogi regarding revenue sharing and development responsibilities.